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Antiretroviral Drugs as the Linchpin for Prevention of HIV 
Infections in the United States
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Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB 
Prevention, Centers for Disease Control and Prevention, Atlanta, GA
Recent advances in the use of antiretroviral drugs for the prevention of HIV infection present 
a historic opportunity to better control the spread of the disease. Despite an estimated 18% 
decline in the number of annual HIV infections between 2008 and 2014 (http://bit.ly/
2ftovat), there were approximately 38 000 new infections in 2014, 70% of which were 
among men who have sex with men (MSM). As a consequence of improved survival with 
antiretroviral therapy (ART), the number of persons living with HIV has increased to 1.1 
million. However, all of these persons are a potential source of new infections to their 
partners, particularly the 15% who do not know that they are infected, as well as those who 
know their HIV status but have not achieved a suppressed viral load (i.e., as a result of 
ART). Each infected person incurs $402 000 in discounted lifetime costs.1
THE INNOVATION
Whereas ART initiation was once reserved for HIV-infected persons who had sustained an 
immunologic decline, it has since been demonstrated that “early” ART markedly reduces 
onward HIV transmission.2 The real-world prevention effects of increased access to 
treatment were documented in Vancouver, British Columbia, between 1996 and 2012. 
Moreover, there is solid evidence that early initiation of ART is associated with reductions in 
severe health outcomes and mortality. Nevertheless, an estimated 61% of HIV transmissions 
in the United States occur from persons who had been diagnosed with HIV but who were not 
retained in care.3 For the prevention of HIV infection in high-risk individuals, several trials 
and demonstration projects have proven the benefit of oral anti-retroviral drugs for pre-
exposure prophylaxis (PrEP) among high-risk MSM, heterosexual men, and women, as well 
as injection drug users.4 Ongoing preclinical and clinical research holds the promise of more 
adherence-friendly PrEP agents.
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Historically, control of infectious diseases has been advanced by chemotherapeutic programs 
as evidenced by declines in syphilis in the 1940s, tuberculosis in the 1960s, and gonorrhea in 
the 1980s. An HIV-specific example has been the success of the prevention of mother-to-
child transmission of HIV. Although a vaccine and a cure for HIV remain elusive, the daily 
accumulation of approximately 130 new infections and the opportunity afforded by the 
innovations of early ART and PrEP demand a concerted effort to maximize the tools we 
have in hand with a bold and sustained campaign.
In 2011, the Centers for Disease Control and Prevention’s (CDC’s) Division of HIV/AIDS 
Prevention (DHAP) implemented a High-Impact Prevention strategy through which 
combinations of scientifically proven, cost-effective, and scalable interventions were 
targeted to the right populations in the right geographic areas.5 National prevention efforts 
have focused on four key areas: widespread testing and linkage to care for infected persons 
to begin early treatment, support for these persons to adhere to ART, universal viral 
suppression, and PrEP services for persons at high risk of HIV acquisition. The national 
goals are to achieve viral suppression in at least 80% of persons living with diagnosed HIV 
and reduce the annual number of new diagnoses by 25%. While the federal government’s 
national goals have been articulated and High-Impact Prevention expresses our agency’s 
strategy, in this article we share a vision for how DHAP intends to more systematically 
promote the use of antiretroviral drugs to reduce new HIV infections.
AN ANTIRETROVIAL DRUG PREVENTION FRAMEWORK
Thomas R. Frieden, the former CDC director, described a six-component wheel as a 
comprehensive approach to control disease.6 At its hub, this wheel has innovation as its 
driving force. In applying this framework for HIV prevention, our innovation consists of 
anti-retroviral drugs used in two ways: early ART for preventing HIV transmission and PrEP 
for the prevention of HIV acquisition. The four spokes of the wheel are the technical 
package, communication, partnership, and effective performance management, and the 
wheel’s rim and sixth component is political commitment.
The technical package consists of a limited number of high-impact interventions that 
together are expected to control HIV. Communication of accurate and timely information to 
the health care community, decision-makers, and the public is intended to engage civil 
society, influence decision-makers, and affect behavior change. Partnerships and coalitions 
are forged with both public- and private-sector organizations, which includes DHAP-funded 
health departments and community-based organizations. Effective performance management 
is carried out through real-time program monitoring, evaluation, and program improvement. 
Finally, political commitment is necessary to obtain the resources and support for action.
COMPONENTS OF THE FRAMEWORK
Here we focus on the four spokes or components of the innovation wheel to maximally use 
antiretroviral drugs for HIV prevention. All these components are necessary for the 
prosecution of successful public health interventions. Table 1 shows selected elements and 
their status within the four components. Some elements consist of published normative 
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documents requiring periodic updates. Other elements might require funding, the pursuit of 
new or broader lines of action, or additional research to improve uptake of PrEP and 
treatment. A notable need is in the strengthening of partnerships and greater coordination 
between government-to-government and government-to-nongovernment entities. The effort 
to treat HIV-infected persons and control the epidemic has had political commitment (the 
rim of the wheel) at the national level. This is evidenced by a $20 billion budget for 
domestic HIV care and treatment in 2016, and a stable $0.9 billion per year for domestic 
HIV prevention between 2011 and 2016.
THE WAY FORWARD
Despite the fact that CDC is in control of neither the funding or the distribution of 
medications related to treatment or PrEP, most elements are within CDC’s sphere of either 
control or influence. The success of the campaign to prevent the transmission of HIV from 
infected mothers to their children demonstrates that such an approach is feasible. CDC is 
committed to addressing the outstanding elements in the spokes of the innovation wheel 
within the context of High-Impact Prevention. There will be increased internal coordination 
at DHAP to advance the components of the wheel, including regular data-driven reviews to 
help focus DHAP’s efforts and understand successes and challenges in the field.
A major share of DHAP’s funding for HIV prevention is aimed at diagnosing people with 
HIV and ensuring that they are swiftly linked to and retained in care so that they can achieve 
and maintain viral suppression. PrEP has been designated as a priority, particularly as a 
targeted prevention initiative for MSM and transgender individuals. Using routine 
monitoring and evaluation as well as special studies, DHAP will rapidly disseminate 
information on the status of PrEP use, early ART initiation, target population behaviors 
associated with these innovations, and updates on the HIV care continuum. Data-to-care is a 
public health strategy that uses HIV surveillance data for public health purposes, especially 
to identify HIV-diagnosed persons not in care and link them to care.
Questions remain about how best to implement early HIV treatment and PrEP. For this 
reason, research is needed to optimally implement various aspects—including behavioral 
and structural interventions—to overcome barriers to early treatment and PrEP. CDC will 
continue to augment public–private partnerships and coordinate with funders of public 
health–oriented research such as the National Institutes of Health. All six components of the 
innovation wheel will be needed to attain a vision of the United States as a place where “new 
HIV infections are rare, and when they do occur, every person … will have unfettered access 
to high-quality, life-extending care.”7(pA3)
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TABLE 1
Components and the Status of Selected Elements of the Four “Spokes” of the Antiretrovirals for HIV 
Prevention Innovation Wheel
Component Selected Elements Status and Potential Actions
Technical package
 Guidelines
 HIV and other laboratory tests, 
including sexually transmitted 
infections
 Tools for reaching target 
population
 Best practices for HIV testing, 
linkage to care, retention in care, re-
engagement in care, and adherence
 Risk-reduction services
Publication and dissemination of guidelines: 
PrEP, nPEP, ART.
Published (updated periodically).
Laboratory guidelines for HIV and STI testing. Published (updated periodically).
Identify target populations. Continue research to close the gap of PLWH 
unaware of their diagnosis; continue research to 
better identify high- risk persons who would most 
benefit from PrEP.
Recommended approaches to optimize HIV 
testing, adherence support (for both PrEP and 
treatment), linkage to care, retention in care, re-
engagement in care.
Partially complete: Web-based training in 
evidence-based prevention services; grantees to use 
the Antiretroviral Treatment Access Study and 
Retention-in-Care methodologies to promote 
linkage to care and retention in care for PLWH, 
respectively; additional research ongoing to 
improve linkage, adherence, and re- engagement in 
HIV care as well as initiation and retention to 
PrEP.
Recommended risk-reduction services, syringe 
services programs, condoms, behavior change 
interventions, referral to mental health and 
substance abuse therapy.
Published (updated periodically).
Communication
 Best practices in use of new 
media
 Education of health care providers 
and beneficiaries
Educate potential patients (PLWH and high-risk 
negatives) on the benefits of PrEP and early 
initiation of ART.
Planned or ongoing but need to ensure quality, 
monitor, and enhance as needed.
 Stakeholder engagement 
including high-risk communities
Educate communities in which there are high 
prevalences of HIV and communities of high-
risk persons on the benefits of PrEP and early 
initiation of ART.
Planned or ongoing but need to ensure quality, 
monitor, and enhance.
Educate primary health care workers on the 
benefits of PrEP and early initiation of ART and 
encourage uptake of guidelines.
Continue and expand funding and support.
Inform stakeholders of the benefits of PrEP and 
early initiation of ART.
Planned or ongoing but need to ensure quality, 
monitor, and enhance.
Maximize use of new media (e.g., smart phones) 
to promote above.
Continue and expand funding and support.
Partnerships Medical associations Enhance current collaborations; begin new ones.
 Associations and societies Federal health agencies Enhance current collaborations per national goals.
 Government–government State and local health departments Funded to implement HIV prevention programs.
 Health care system Clinics and health care organizations Enhance current collaborations per national goals.
 Community Community-based organizations Funded to implement HIV prevention programs.
Advocacy organizations Enhance current collaborations per national goals.
Private sector Enhance current collaborations per national goals.
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Component Selected Elements Status and Potential Actions
Performance management
 Monitoring and evaluation
 HIV surveillance, including the 
care continuum
Monitor progress of grantees in implementing 
PrEP and early initiation of ART and document 
best practices.
Complete best practices in the use of PrEP and 
early initiation of ART.
 Behavioral surveillance
 Best practices documentation
Conduct health services research to assess the 
impact of the new programs.
Planned or ongoing but need to ensure quality, 
monitor, or enhance.
 Research
 Transmitted drug resistance 
surveillance
Monitor transmitted drug resistance to ensure 
that tenofovir/emtricitabine remains the first-
choice PrEP agent.
Ongoing program; may require development and 
funding of surveillance for transmitted drug 
resistance in PrEP patients.
Note. ART = antiretroviral therapy; nPEP = nonoccupational postexposure prophylaxis; PLWH = persons living with HIV; PrEP = pre-exposure 
prophylaxis; STI = sexually transmitted infection.
Source. The components and innovation wheel concept were described by Frieden.7
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